LUPIN BREAKS OUT TO NEW HIGH FROM OVER 9-YEAR BASE
On this monthly chart LUPIN just broke-out from about 9 and half years long base. It is now trading slightly above the breakout point. If it sustains above 2025 level, we can see some significant rally. The momentum is pretty strong as indicated by RSI that is rising above 60. Its relative performance to CNX 500 is strong and is rising above its 12-month MA. Relative performance to CNX-Pharma index is also rising.
The company is primarily engaged in development & commercialisation of wide range of branded & generic formulations, biotechnology products, and APIs extending to global markets. On the fundamentals side the company has revenue growth of 20%, pre-tax margin of 12%, ROE of 13%, and is debt-free. These metrics indicate the good health of the company. Over the last 6 quarters both sales and EPS have been growing significantly.
No recommendation. Only personal analysis for educational purposes. Please consult your Financial Advisor for any investment or buy or sell decisions in the financial markets.
The company is primarily engaged in development & commercialisation of wide range of branded & generic formulations, biotechnology products, and APIs extending to global markets. On the fundamentals side the company has revenue growth of 20%, pre-tax margin of 12%, ROE of 13%, and is debt-free. These metrics indicate the good health of the company. Over the last 6 quarters both sales and EPS have been growing significantly.
No recommendation. Only personal analysis for educational purposes. Please consult your Financial Advisor for any investment or buy or sell decisions in the financial markets.
Raju KMS Datla
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.